RxDoctor Payments Data

Steve Simpson, MD

Interventional Cardiology · Fort Worth, TXNPI 1639377179

Payments from drug & device makers

$14,927in general payments, 2019–2025

Across 329 payments — averaging $45.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$9K
  • Novartis$861
  • E.r. Squibb & Sons, L.L.C.$634
  • Johnson & Johnson$592
  • AstraZeneca$541
  • Merck$458
  • plus $3K from 27 others

What the payments were for

  • Travel & lodging$8,83559%
  • Food & beverage$5,82239%
  • Education$2532%
  • Entertainment$170%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,927 in reported general payments places this provider in the 60th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$356,816
Medicare patients
720
Services billed
2,769

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban596$718,451
EntrestoSacubitril/Valsartan166$209,602
XareltoRivaroxaban120$160,496
JardianceEmpagliflozin58$79,548
MultaqDronedarone Hcl33$53,766
BrilintaTicagrelor33$29,954
Repatha SureclickEvolocumab15$17,339
Ranolazine ErRanolazine75$7,057
Valsartan268$6,731
Nifedipine ErNifedipine223$6,115
Atorvastatin Calcium470$5,366
Metoprolol Succinate362$5,151
Rosuvastatin Calcium315$3,856
ClopidogrelClopidogrel Bisulfate310$3,588
Carvedilol364$3,535

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$210$718,451596 claims
NovartisEntresto$861$209,602166 claims
Johnson & JohnsonXarelto$592$160,496120 claims
Boehringer IngelheimJardiance$126$79,54858 claims
Sanofi-aventis U.S. LLCMultaq$381$53,76633 claims
AstraZenecaBrilinta$541$29,95433 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →